Protocol for updating the Evidence database of the Best Practice Portal
Protocol for updating the Evidence database of the Best Practice Portal
<em class="pub-author">EMCDDA,</em>
<em class="pub-local">Lisbon,</em>
<em class="pub-date"><span class="date-display-single" property="dc:date" datatype="xsd:dateTime" content="2020-12-14T00:00:00+00:00">December 2020</span></em>


                    <div class="summary">
        <h2 class="publications-summary">Summary</h2>
        <div class="field field-name-field-summary field-type-text-long field-label-hidden"><div class="field-items" readability="9"><div class="field-item even" readability="13">The Evidence database is a core component of the EMCDDA’s Best Practice Portal. The portal is a resource for professionals, policymakers and researchers in the drugs field and provides information on the available evidence on drug-related prevention, treatment and harm reduction, focusing on the European context. The evidence is compiled following an explicit methodological process which is described in this document.
        <div class="publication-attachments pdf">
            <strong>Download as PDF</strong>                                                                                                    </div>








            <div class="main-subject"><h3 class="field-label"><i class="fa fa-tag"/> Main subject: </h3><p class="field-items"><span class="field-item"><a href="/topic/best-practice">best practice</a></span></p></div>
Marijuana: the other “pandemic” in Europe
Marijuana: the other “pandemic” in Europe

At a time the main focus of all the sectors of the society is on the COVID pandemic, there is another insidious problem developing covertly: the drug. If the pandemic has undoubtedly an impact on the health, the economy, and the society at large, it has also affected the availability and through the confinement of the use of the different drugs. And this is a real concern for the EMCDDA (1) but also for the other international institutions such as UNODC (2) and WHO (3).

Aware of these problems and to ensure the youth, parents, and public will not be deprived of vital information on the harmful effects of drug use, the Foundation for a Drug Free Europe (4) and its teams of volunteers of the hundred Say No To Drugs associations and groups existing in some twenty European countries,  continued their actions of prevention education about drugs.

Indeed, wearing their turquoise tee-shirts and using the requested outdoors protections (masks, gloves, etc.) for distributions, the volunteers were found either outdoors in streets or parks, or behind a booth, handing-out their booklets The Truth About Drugs (5), or proposing a display of booklets to shopkeepers. Meanwhile, other volunteers were organizing educative series of lectures online on: what are drugs, their actions, etc. followed by discussion. They were rather successful.

Where do we stand at in Europe?

At the European level, The EMCDDA in a series of rapid studies, has also reported on the impact of COVID-19 on drug use and associated problems, help-seeking, service provision and the operation of the drug market.

In the last European Drug Report 2020 statistics EMCDDA reported an increasing amount of seizures being: 40% Herbal cannabis, 29% Cannabis resin (668 tonnes), 2% Cannabis plant, 10% Cocaine and crack, 6% Amphetamines, 5% Heroin, 3% MDMA, and 6% Other substances.

For Cannabis, from surveys of the general European population, it is estimated that around 1 % of adults are daily or almost daily cannabis users. The majority of these (60 %) are under 35 and around three quarters are male. Cannabis is always the world’s most popular illegal drug with the highest level of availability. The Chinese called it “the drug that takes away the mind”.

The number and quantity of cocaine seizures are now the highest ever reported, with over 181 tonnes of the drug seized in 2018. Belgium, Spain and the Netherlands are key countries for the interception of large quantities. Cocaine is now playing a more important role in the European drug problem. The cocaine market also appears an important driver for drug-related violence.  

Regarding heroin and other opioids, 1,3 millions of people are high-risk opioid users and opioids are found in 82% of the fatal overdoses. After cannabis and cocaine, heroin is the third most common substance involved in drug-related acute toxicity presentations monitored by Euro-DEN Plus in 2018.

Is there a solution?

The first point should be the application by the governments (6) of the article 33 of the Convention on the Rights of the Child. Then, fighting the drug scourge can be achieved by education of the youth and by prevention, spreading the message on the truth about drugs from the streets to the working place via the classrooms and everywhere. Indeed, empowering the youth with facts on what drugs are and what they do, is giving them the choice to decide to live a drug free life and reach their goals in a safe and sane society.

References

1-EMCDDA: European Monitoring Center on Drugs and Drug Addiction. Find more on https://www.emcdda.europa.eu/system/files/publications/13238/TD0420439ENN.pdf European Report 2020 – Key Issues.

2-UNODC: United Nations Office on Drugs and Crime, located in Vienna (Austria).

“Know more, care more. Addressing the world drug problem requires responses that are based on facts, solidarity and compassion.”  Ms. Ghada Waly, UNODC Executive Director

3-WHO: World Health Organisation; its main objective is “the attainment by all peoples of the highest possible level of health.

4-FDFE: Established in 2004, a non-profit NGO, with an operating office located in Brussels. Visit: www.fdfe.eu Part of the European Commission Transparency Register.

5-The website www.DrugFreeWorld.org, partnering with FDFE is providing the 14 The Truth About Drugs prevention booklets in 17 languages, a DVD of testimonies and an Educator Guide.

Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)
Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

EMCDDA,
Lisbon,
November 2020

Summary

This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020. On the basis of the Risk Assessment Report, on 2 September 2020, the Commission decided that isotonitazene should be included in the definition of ‘drug’, in the Annex to Framework Decision 2004/757/JHA. Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with Commission Delegated Directive (EU) 2020/1687 by 3 June 2021.

Download as PDF

Table of contents

  • Statement regarding the United Kingdom
  • Foreword
  • EMCDDA Initial Report on isotonitazene
  • Risk Assessment Report on a new psychoactive substance: isotonitazene
  • Technical report on isotonitazene
  • Participants of the risk assessment meeting, 26 May 2020

Main subject:

NPS